

IPCA PHARMA NIGERIA LIMITED

DIRECTORS' REPORT

To
The Members
Ipca Pharma Nigeria Ltd.

Your Directors have pleasure in presenting their Annual Report together with the audited statement of accounts for the year ended 31st March, 2017.

FINANCIAL RESULTS

Particulars	For the year ended 31 st March 2017 (Rs. in lacs)	For the year ended 31 st March 2016 (Rs. in lacs)
Total Income	1488.14	2278.15
Total Expenditure	1521.18	2084.90
Financial Cost	73.63	147.80
Depreciation	14.90	16.66
Profit before tax	(121.57)	28.79
Less: Provision for taxation		
Current	5.71	8.70
Deferred	(0.60)	10.79
Earlier Year's Tax	--	--
Profit after tax but before extraordinary items	(126.68)	9.30
Extraordinary Items		
Other Comprehensive Income	(96.89)	(5.35)
Total Comprehensive Income for the period (Comprising Profit /(Loss) and Other Comprehensive Income for the period)	(223.57)	3.95
YOUR DIRECTORS RECOMMEND THE FOLLOWING APPROPRIATIONS		
Surplus in Other Equity as per last Balance Sheet	314.26	304.96
Net Profit for the year	(126.68)	9.30
Less:		
Transfer to General Reserve	--	--
Balance as at year end	187.58	314.26

INCORPORATION

Your Company is a wholly owned subsidiary of Ipca Laboratories Limited, India. The business activity of the company is importation and marketing of pharmaceutical formulations as well as Active Pharmaceutical Ingredients (APIs).

Your company is in process of registering more pharmaceuticals in Nigeria as well as increasing the field force strength to cover more geographies for promoting the company's products in the Nigerian market.

IPCA PHARMA NIGERIA LIMITED

TRANSFER TO GENERAL RESERVE

During the year under report, the Company has not transferred any amount to General Reserve Account.

OPERATIONS

The total income for the financial year under report was Rs. 1,488.14 lacs (Previous year Rs. 2,278.15 lacs) and the operations have resulted in a net loss of Rs. 126.68 lacs (Previous year net profit of Rs. 9.30 lacs). During the year under report there was no change in the nature of Company's business.

MATERIAL CHANGES AND COMMITMENTS AFTER THE END OF THE FINANCIAL YEAR

No material changes or commitments affecting the financial position of the Company have occurred between the end of the financial year to which financial statements in this report relate and the date of this report.

SHARE CAPITAL

The paid-up equity share capital of the Company as at 31st March, 2017 is Rs.188.94 lacs. The Company currently has no outstanding shares issued with differential rights, sweat equity or ESOS.

SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

The Company does not have any subsidiary, joint venture and associate companies.

DIVIDEND

In order to conserve resources of the company, no dividend has been proposed by the board for the financial year under report.

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

- i) that in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- ii) that your Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year March 31, 2017 and of the loss of the Company for the year;

IPCA PHARMA NIGERIA LIMITED

- iii) that your Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv) that your Directors have prepared the annual accounts on a going concern basis.
- v) that your Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.
- vi) that your Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

FIXED DEPOSIT

During the year under review, the Company has not accepted any fixed deposits within the meaning of Section 73 of the Companies Act, 2013.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The Company has not given any loans or guarantees or made any investment in any other Company.

AUDITORS, AUDIT REPORT AND AUDITED FINANCIAL STATEMENTS:

M/s Amobi Nwokafor & Co., Chartered Accountants, retire as auditors and, being eligible, offer themselves for re-appointment.

The Auditors' Report read with the notes to the accounts referred to therein are self-explanatory and therefore, do not call for any further comments.


PARTICULARS OF EMPLOYEES

The Company had no employees covered under Section 197 of the Companies Act, 2013 read with rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force).

ACKNOWLEDGEMENTS

Your Directors place on record their profound admiration and sincere appreciation of the continued hard work put in by employees at all levels. Your Directors also place on record their appreciation for the continued co-operation and support extended to the Company by the trade and the customers.

For and behalf of the Board



Manish Jain

Chairman


May 28, 2017

IPCA PHARMA NIGERIA LIMITED
Balance Sheet as at March 31, 2017

Particulars	Note Ref.	(₹ Lakhs)	(₹ Lakhs)	(₹ Lakhs)
		As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	1	31.20	50.49	44.69
(b) Capital work-in-progress		-	-	-
(c) Investment Property		-	-	-
(d) Goodwill		-	-	-
(e) Other Intangible assets		-	-	-
(f) Intangible assets under development		-	-	-
(g) Biological Assets other than bearer plants		-	-	-
(h) Financial Assets		-	-	-
(i) Investments		-	-	-
(ii) Trade receivables		-	-	-
(iii) Loans		-	-	-
(iv) Others		-	-	-
(i) Deferred tax assets (Net)		-	-	-
(j) Other Non-current assets	3	4.08	26.50	18.42
		35.28	76.99	63.11
(2) Current Assets				
(a) Inventories	4	440.06	170.65	777.92
(b) Financial Assets				
(i) Investments		-	-	-
(ii) Trade receivables	5	28.49	47.72	9.82
(iii) Cash and cash equivalents	6	569.43	882.31	371.95
(iv) Bank balances other than (iii) above		-	-	-
(v) Loans	2	2.27	12.05	3.81
(vi) Others	7	2.55	5.75	7.56
(c) Current Tax Assets (Net)		-	-	-
(d) Other current assets	3	53.25	41.70	33.31
		1,096.05	1,160.18	1,204.37
Total Assets		1,131.33	1,237.17	1,267.48
EQUITY & LIABILITIES				
Equity				
(a) Equity Share capital	8	188.94	188.94	188.94
(b) Other Equity	9	178.63	402.20	398.25
		367.57	591.14	587.19
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings		-	-	-
(ii) Trade payables		-	-	-
(iii) Other financial liabilities		-	-	-
(b) Provisions		-	-	-
(c) Deferred tax liabilities (Net)		6.30	10.89	-
(d) Other Non-current liabilities		-	-	-
		6.30	10.89	-
(2) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings		-	-	-
(ii) Trade payables	11	751.58	619.59	675.96
(iii) Other financial liabilities		-	-	-
(b) Other current liabilities	12	0.99	1.75	4.33
(c) Provisions	10A	-	5.02	-
(d) Others		-	-	-
(e) Current Tax Liabilities (Net)		4.89	8.78	-
		757.46	635.14	680.29
Total Equity and Liabilities		1,131.33	1,237.17	1,267.48

Statement of Significant Accounting policies and Other Explanatory Notes form part of the Balance Sheet and Statement of Profit and Loss.

For and on behalf of the Board


Manish Jain
Director


Shashil Mondansa
Director

Place: Mumbai
Date: May 28, 2017

IPCA PHARMA NIGERIA LIMITED

Statement of Profit and Loss for the year ended 31st March, 2017

Particulars	Note Ref.	(₹ Lakhs) 2016-17	(₹ Lakhs) 2015-16
I Revenue from operations	13	1,462.26	2248.74
II Other income	14	25.88	29.41
III Total Income (I+II)		1,488.14	2,278.15
IV Expenses			
Cost of materials consumed		-	-
Purchases of stock-in-trade	15	1,201.43	817.77
Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	16	(269.41)	607.27
Employee benefits expense	17	49.33	133.66
Finance costs	18	73.63	147.80
Depreciation and amortisation expense	1	14.90	16.66
Other expenses	19	539.50	532.74
Foreign exchange (gain)/loss-net		0.33	(6.54)
Total Expenses (IV)		1,609.71	2,249.36
V Profit/(loss) before exceptional items and tax (III-IV)		(121.57)	28.79
VI Exceptional Items		-	-
VII Profit/ (loss) before tax (V-VI)		(121.57)	28.79
VIII Tax expense:			
(1) Current tax		5.71	8.70
(2) Deferred tax		(0.60)	10.79
IX Profit/ (loss) for the period from continuing operations (VII-VIII)		(126.68)	9.30
X Profit/ (loss) from discontinued operations			
XI Tax expense of discontinued operations			
XII Profit/ (loss) from discontinued operations (after tax) (X-XI)		-	-
XIII Profit/ (loss) for the period (IX+XII)		(126.68)	9.30
XIV Other Comprehensive Income			
A (i) Items that will not be reclassified to profit or loss			
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B (i) Items that will be reclassified to profit or loss			
Exchange difference in translating the financials statement of foreign operation		(96.89)	(5.35)
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
		(96.89)	(5.35)
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		(223.57)	3.95
XVI Earnings per equity share (for continuing operation) :			
(1) Basic		(0.25)	0.02
(2) Diluted		(0.25)	0.02

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss

For and on behalf of the Board


Manish Jain
Director


Shashil Mendonsa
Director

Place: Mumbai
Date: May 28, 2017

IPCA PHARMA NIGERIA LIMITED
Cashflow statement for the year ended 31st March 2017

Particulars	(₹ Lakhs) 2016-17	(₹ Lakhs) 2015-16
CASH FLOW FROM OPERATING ACTIVITIES		
1. Net profit/(loss) before taxation	(121.57)	28.79
Adjustments for :		
Depreciation	14.90	16.66
Bad Debts written off/(recovered) (net)		(5.06)
Foreign Exchange loss / (Gain)		
Profit on sale of Fixed asset (net)	(2.02)	(1.44)
Asset scrapped	(0.84)	-
Miscellaneous balances written off/back (net)	- <u>12.04</u>	<u>10.16</u>
2. Operating profit before working capital changes	(109.53)	38.95
Decrease/(Increase) in Receivables	40.12	(57.43)
Decrease/(Increase) in Inventories	(269.41)	607.27
Increase/(Decrease) in Sundry creditors & provisions	126.21 <u>(103.08)</u>	(53.93) <u>495.91</u>
3. Cash generated from operation	(212.61)	534.86
Movement in Foreign Currency Translation Reserve	(83.31)	(7.65)
Income Tax Refund / (Paid)	(6.64) <u>(89.96)</u>	1.77 <u>(5.88)</u>
Net cash from operating activities (A)	<u>(302.57)</u>	<u>528.98</u>
CASH FLOW FROM INVESTING ACTIVITIES		
Sale of Fixed Assets	7.54	5.04
Purchase of Fixed Assets	(17.85) <u>(10.32)</u>	<u>(23.66)</u> (18.62)
Net cash from / (used) in investing activities (B)	<u>(10.32)</u>	<u>(18.62)</u>
Net increase/(decrease) in cash and cash equivalents (A + B)	<u>(312.89)</u>	<u>510.36</u>
Cash and cash equivalents at beginning of period	882.31	371.95
Cash and cash equivalents at end of period	<u>569.43</u>	<u>882.31</u>
Components of Cash & Cash equivalents:		
Cash and Cheques on hand	1.03	1.97
Balance with Banks	374.88	414.24
Fixed Deposit with Banks	193.52	466.09
	<u>569.43</u>	<u>882.31</u>

For and on behalf of the Board


Manish Jain
 Director


Shashil Mendonsa
 Director

Place: Mumbai
 Date: May 28, 2017


IPCA PHARMA NIGERIA LIMITED

Statement of change in equity for the year ended March 31, 2017

(₹ Lakhs)

Particulars	Equity share capital	Reserves & Surplus		Other Reserves	Total Equity
		Security premium	Retained Earnings	Foreign Currency Translation reserve	
As at April 01, 2015	188.94	93.29	304.96		587.19
Profit for the period			9.30		9.30
Exchange difference in translating the financial statement of foreign operation				(5.35)	(5.35)
Balance as on March 31, 2016	188.94	93.29	314.26	(5.35)	591.14
Profit for the period			(126.68)		(126.68)
Exchange difference in translating the financial statement of foreign operation				(96.89)	(96.89)
Balance as on March 31, 2017	188.94	93.29	187.58	(102.23)	367.57

For and on behalf of the Board


Manish Jain
Director
Shashil Mendonsa
DirectorPlace: Mumbai
Date: May 28, 2017

IPCA PHARMA NIGERIA LIMITED

1. Property plant and Equipments

(₹ Lakhs)

Particulars	GROSS BLOCK									DEPRECIATION									NET BLOCK		
	Opening as on 01/04/15	Additions	Sales / Adjustment	Foreign Exchange fluctuation Reserve	Opening as on 01/04/16	Additions	Sales / Adjustment	Foreign Exchange fluctuation Reserve	Total as on 31/03/17	Opening as on 01/04/15	Sales / Adjustment	For the year	Foreign Exchange fluctuation Reserve	Opening as on 01/04/16	Sales / Adjustment	For the year	Foreign Exchange fluctuation Reserve	Total as on 31/03/17	As on 31/03/17	As on 31/03/16	As on 31/03/15
Leasehold Property	14.22	0.18	-	0.81	15.21	5.09	-	(5.88)	14.81	8.11	-	0.95	0.47	9.53	-	1.71	(3.81)	7.43	7.18	5.68	6.11
Office Equipment	9.82	7.39	(5.70)	0.55	11.88	-	-	(4.43)	7.43	7.79	(5.13)	1.17	0.44	4.27	-	0.67	(1.72)	3.42	4.01	7.59	1.83
Computers	4.34	-	-	0.25	4.59	-	-	(1.71)	2.87	3.04	-	0.57	0.18	3.78	-	0.67	(1.51)	2.95	(0.08)	0.80	1.30
Furniture & Fixture	11.89	3.93	-	0.68	16.49	-	-	(6.16)	10.33	7.45	-	1.51	0.44	9.40	-	1.21	(3.69)	6.92	3.41	7.09	4.44
Motor Vehicles	61.73	12.16	(5.42)	3.52	71.99	12.76	(13.18)	(28.90)	44.87	30.72	(2.40)	12.46	1.87	42.65	(7.66)	10.44	(17.44)	27.99	16.68	29.34	31.01
PER BALANCE SHEET	101.80	23.66	(11.13)	5.80	120.13	17.85	(13.18)	(44.89)	79.91	57.11	(7.53)	16.66	3.40	69.64	(7.66)	14.90	(26.17)	48.71	31.20	50.49	44.69
Previous Year	135.57	27.31	(43.34)	(17.74)	101.80	23.66	(11.13)	5.80	120.13	84.10	(32.77)	19.00	(13.22)	57.11	(7.53)	16.66	3.40	69.64	50.49	44.69	51.47

IPCA PHARMA NIGERIA LIMITED
Statement of Significant Accounting policies and Other Explanatory Notes

Background

ACCOUNTING POLICIES

a) Accounting convention

The Financial Statements have been prepared to comply in all material respects with the notified Indian accounting standards (Ind AS) prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The financial statements have been prepared under the historical cost convention, on an accrual basis of accounting.

For all periods upto and including the year ended March 31, 2016 the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act, 2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).

The Company presents assets and liabilities in the balance sheet based on current/non-current classification.

An asset is current when :

- It is expected to be realised or intended to be sold or consumed in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is expected to be realised within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when :

- It is expected to be settled in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for atleast twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The accounting policies adopted in the preparation of financial statements are consistent with those used in the previous year.

b) Conversion In to Indian Rupees:

The translation of financial statements into Indian Rupees is done in accordance with Ind AS 21 (Revised) "Effects of Changes in Foreign Exchange" notified by the Companies (Accounting Standards) Rules 2015. The resultant Foreign Currency Translation Reserve is shown separately under other comprehensive reserves forming part of Other Equity.

The Assets and Liabilities are translated at closing rate except share capital, which is translated at the rate as on transaction date. The income and expenditure are translated at a rate nearing the average rate during the year.

c) Property, Plant and Equipment: The Property, plant and equipment existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in Ind AS 101 " First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value.

d) Depreciation: Depreciation is computed on straight line basis over the estimated useful life of the assets at the following rates:

Leasehold improvement	10%
Office Equipment	10%
Computers and Accessories	20%
Furniture and Fixtures	10%
Motor Vehicles	20%

e) Inventories: Inventories are valued on First in first out (FIFO) method at lower of landed cost or net realizable value (NRV).

f) Revenue Recognition: Sales of goods is recognized at the point of dispatch to customer.

g) Taxation

Current Tax: Current Tax is calculated as per the provisions of the Income Tax in Nigeria.

Deferred Tax: Deferred Tax is recognized in respect of all timing differences that have originated but not reversed at the balance sheet date..

h) Cash and Cash Equivalents: Cash and cash equivalents in the Balance Sheet comprise cash at bank, cheques on hand, cash in hand and short term investments with an original maturity of three months or less.

i) Foreign Exchange Transactions:

i) Transactions denominated in foreign currency are recorded at the exchange rate on the date of transaction. The exchange gain/loss on settlement / negotiation during the year is recognized in the Statement of Profit and Loss.

ii) Current assets and current liabilities at the end of the year are converted at the year end rate and the resultant gain or loss is accounted for in the Statement of Other Comprehensive Income.

IPCA PHARMA NIGERIA LIMITED

Notes to financial statements as at and for the year ended March 31, 2017

2 Financial Assets - Loans							
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)		
	Current	Non-Current	Current	Non-Current	Current	Non-Current	
(a) Security Deposit	1.47	-	2.35	-	2.22	-	
(b) Loans :							
- Employees	0.80	-	9.70	-	1.59	-	
- Others	-	-	-	-	-	-	
Total	2.27	-	12.05	-	3.81	-	
3 Other Non-Financial Assets							
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)		
	Current	Non-Current	Current	Non-Current	Current	Non-Current	
Advance Tax	-	4.08	-	7.04	-	8.73	
Prepaid expenses	26.02	-	41.70	19.46	33.31	9.69	
Advances:							
- Employees	1.99	-	-	-	-	-	
- Others	25.24	-	-	-	-	-	
Total	53.25	4.08	41.70	26.50	33.31	18.42	
4 INVENTORIES							
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)		
	Current	Non-Current	Current	Non-Current	Current	Non-Current	
Finished goods							
In Hand - Traded	440.06	-	170.65	-	777.92	-	
Total	440.06	-	170.65	-	777.92	-	
5 Financial Assets - Trade receivables (Unsecured, at amortised cost)							
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)		
	Current	Non-Current	Current	Non-Current	Current	Non-Current	
Trade receivables							
Unsecured, considered good	28.49	-	2.14	-	0.12	-	
Unsecured, considered doubtful	0.51	-	42.12	-	44.68	-	
Less: Provision for doubtful debts	(0.51)	-	(42.12)	-	(44.68)	-	
	28.49	-	2.14	-	0.12	-	
Unsecured, considered good	-	-	45.58	-	9.70	-	
Total	28.49	-	47.72	-	9.82	-	
6 Financial Assets - Cash & Cash Equivalents							
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)		
	Current	Non-Current	Current	Non-Current	Current	Non-Current	
Cash & Cash Equivalents							
Cash on hand	1.03	-	1.97	-	3.93	-	
Balances with banks	374.88	-	414.24	-	168.98	-	
Cheques, drafts on hand	-	-	-	-	-	-	
Fixed deposit with bank	193.52	-	466.09	-	199.04	-	
Total	569.43	-	882.31	-	371.95	-	
7 Financial Assets - Others							
Particulars	As at 31/03/2017 (₹ Lakhs)		As at 31/03/2016 (₹ Lakhs)		As at 01/04/2015 (₹ Lakhs)		
	Current	Non-Current	Current	Non-Current	Current	Non-Current	
Other income receivables	2.55	-	5.75	-	7.56	-	
Total	2.55	-	5.75	-	7.56	-	
8 Equity Share Capital							
Particulars	As at 31/03/2017		As at 31/03/2016		As at 01/04/2015		
	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)	
Face Value							
Class of Shares		Naira 1 each		Naira 1 each		Naira 1 each	
Authorised Capital*	52,000,000		52,000,000		52,000,000		
Issued, Subscribed and Paid up Capital							
Issued & Subscribed & Paid up	51,589,190	188.94	51,589,190	188.94	51,589,190	188.94	
Bank Guarantee (Ind AS)	-	-	-	-	-	-	
Total	51,589,190	188.94	51,589,190	188.94	51,589,190	188.94	

IPCA PHARMA NIGERIA LIMITED

Notes to financial statements as at and for the year ended March 31, 2017

Disclosures:

i) Reconciliation of Shares

Particulars	Equity Shares		Equity Shares		Equity Shares	
	As at 31/03/2017		As at 31/03/2016		As at 01/04/2015	
	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)
Shares outstanding at the beginning of the year	51,589,190	188.94	51,589,190	188.94	51,589,190	188.94
Shares issued during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	51,589,190	188.94	51,589,190	188.94	51,589,190	188.94

ii) Details of Shareholding in excess of 5%

Name of Shareholder	Equity Shares		Equity Shares		Equity Shares	
	As at 31/03/2017		As at 31/03/2016		As at 01/04/2015	
	No. of shares	%	No. of shares	%	No. of shares	%
Ipcalaboratories Ltd	51,589,190	100.00	51,589,190	100.00	51,589,190	100.00

9 Other Equity

Particulars	As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
	(₹ Lakhs)	(₹ Lakhs)	(₹ Lakhs)
a) Retained Earnings	187.58	314.26	304.96
b) Securities Premium Account	93.29	93.29	93.29
c) OCI Reserve	-	-	-
-Foreign Currency Translation Reserve	(102.23)	(5.35)	-
Total	178.63	402.20	398.25

10 Current Tax Liabilities (Net)

Particulars	As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
	(₹ Lakhs)	(₹ Lakhs)	(₹ Lakhs)
Provision for income tax	4.89	8.78	-
Total	4.89	8.78	-

10A Provisions

Particulars	As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
	(₹ Lakhs)	(₹ Lakhs)	(₹ Lakhs)
Provision for breakage damage expiry	-	5.02	-
Total	-	5.02	-

The disclosure of provisions movement as required under the provisions of Ind AS 37 is as follows:-

Particulars	31-Mar-2017	31-Mar-2016
	(₹ Lakhs)	(₹ Lakhs)
(i) Provision for breakage/damage		
Balance at the beginning of the period	5.02	-
Provisions made during the period	-	5.02
Utilisations during the period	(5.02)	-
Provision at the end of the period	-	5.02

11 Financial Liabilities - Trade Payables

Particulars	As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
	(₹ Lakhs)	(₹ Lakhs)	(₹ Lakhs)
Trade Payables			
- Micro Small and Medium Enterprises	-	-	-
- Others	751.58	619.59	675.96
Total	751.58	619.59	675.96

12 Other Non-financial liabilities

Particulars	As at 31/03/2017		As at 31/03/2016		As at 01/04/2015	
	(₹ Lakhs)		(₹ Lakhs)		(₹ Lakhs)	
	Current	Non-Current	Current	Non-Current	Current	Non-Current
Advance received from customers	-	-	-	-	4.33	-
Duties and Taxes Payable	0.99	-	1.75	-	-	-
Total	0.99	-	1.75	-	4.33	-

IPCA PHARMA NIGERIA LIMITED

Notes to financial statements as at and for the year ended March 31, 2017

13 Revenue From Operation

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Sale of products	1,462.26	2,248.74
Sale of Service	-	-
Other Operating revenue	-	-
Total	1,462.26	2,248.74

14 OTHER INCOME

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Profit on sale of assets	2.02	1.44
Bad Debts recovered	-	5.06
Miscellaneous Balance Written back (net)	-	-
Miscellaneous income	23.86	22.91
Total	25.88	29.41

15 PURCHASE OF STOCK IN TRADE

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Purchase	1,201.43	817.77
AS PER STATEMENT OF PROFIT & LOSS	1,201.43	817.77

16 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Inventory Adjustments - Finished Goods		
Traded Goods		
Stock at Commencement	170.65	777.92
Less : Stock at Closing	440.06	170.65
AS PER STATEMENT OF PROFIT & LOSS	(269.41)	607.27

17 EMPLOYEE BENEFITS EXPENSE

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Salaries	40.10	118.37
Staff Welfare	8.28	11.07
Recruitment and Training	0.95	4.22
Total	49.33	133.66

18 FINANCE COST

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Cash Discount	73.63	147.80
Total	73.63	147.80

19 Other Expenses

Particulars	2016-17 (₹ Lakhs)	2015-16 (₹ Lakhs)
Power, fuel, gas and water charges	28.73	57.34
Repairs		
- Building	6.38	4.70
-Others	6.73	6.27
Bank Charges	13.36	7.61
Insurance	15.51	24.14
Rent	25.90	59.78
Rates and taxes	-	6.69
Freight, forwarding and transportation	108.53	121.49
Field staff expenses	99.16	51.35
Communication expenses	8.75	8.56
Travelling expenses	114.08	102.59
Audit Fee	1.92	1.95
Professional charges	-	3.67
Printing and stationery	5.60	5.52
Books, Subscription and Software	0.19	0.40
Product promotion expenses	-	6.91
Asset Scraped	(0.84)	-
Marketing and Sales administration expenses	54.99	27.37
Product Registration Expenses	18.91	20.74
Distribution charges	12.03	-
Miscellaneous expenses	19.57	15.66
PER STATEMENT OF PROFIT & LOSS	539.50	532.74

20 Disclosure as required by Ind AS - 24 "Related Party Transactions" notified by the Companies (Accounting Standards) Rules 2015.

Relationship

Country of Incorporation

Entities where control exists

Ipca Laboratories Limited – Holding Company

India

Key Management Personnel

Manish Jain

Director

India

Shashil Mendonsa

Director

India

James Awolola

Director

Nigeria

Transactions

(₹ Lakhs)

Description	Entities where control exists	Key Management	Total
<u>Goods and Services Purchased</u>			
Ipca Laboratories Limited	1,201.43		1,201.43
Previous Year	726.71		726.71
Total	1,201.43	-	1,201.43
Previous Year	726.71	-	726.71
<u>Remuneration</u>			
James Awolola		6.99	6.99
Previous Year		10.44	10.44
S.V Kotian		-	-
Previous Year		0.91	0.91
Total	-	6.99	6.99
Previous Year	0.00	11.35	11.35
<u>Sitting fees</u>			
James Awolola		0.11	0.11
Previous Year		0.21	0.21
Total	-	0.11	0.11
Previous Year	-	0.21	0.21
<u>Balances as on 31st March 2017</u>			
<u>Payable</u>			
Ipca Laboratories Limited	633.97		633.97
Previous Year	432.42		432.42
Total	633.97	-	633.97
Previous Year	432.42	-	432.42

21 Earning per Share

The earning per share is calculated by dividing the profit after tax by weighted average no. of shares outstanding for basic and diluted EPS.

Particulars	2016-17	2015-16
Profit after tax (₹ Lakhs)	(126.68)	9.30
Equity Shares Outstanding (Nos)		
-Opening	51,589,190	51,589,190
-Issued during the year	-	-
-Closing	51,589,190	51,589,190
Weighted Average no. of shares outstanding (Nos.) - Basic	51,589,190	51,589,190
Weighted Average no. of shares outstanding (Nos.) - Diluted	51,589,190	51,589,190
Nominal value of equity share	N 1 each	N 1 each
Earning per share (Rs.)		
- Basic	(0.25)	0.02
- Diluted	(0.25)	0.02

22 Prior period comparatives :

Previous year's figures have been regrouped or rearranged wherever necessary.

23 The annual accounts have been prepared on going concern basis.

24 The Company is 100% subsidiary of Ipca Laboratories Limited. The accounts have been prepared in Indian Rupees for the purpose of attachment to the accounts of the holding company to comply with the provisions of Indian Companies Act.

25 The Balance Sheet, Statement of Profit and Loss, Statement of changes in equity, Cash Flow Statement, Statement of significant accounting policy and other explanatory notes form an integral part of the financial statements of the company for the year ended on March 31, 2017.

For and on behalf of the Board,


Manish Jain
Director


Shashil Mendonsa
Director

Place: Mumbai
Date: May 28, 2017